Randomized Controlled Trials (RCTs) are the gold standard of medical research as random assignment approach helps eliminate bias and yields the most reliable evidence on whether a treatment truly works. Since RCTs sit at the top of the evidence hierarchy, retractions can send ripple effects across the entire system. A fraudulent study with fabricated data or results can influence the credibility of systematic reviews and meta-analyses, and those distortions can quietly shape clinical practice guidelines that influence real-world medical care.
In a recent study, researchers set out to investigate how many retracted randomized clinical trials were linked to superretractors (authors with the most retractions) and to highly cited authors with multiple retractions.
They found that just 6 superretractors were co-authors on 22% of all retracted clinical trials studied, 5 were based in Japan, and 1 was from Germany. Also, a group of 18 top-cited scientists were involved in 25% of all retracted trials. The retractions were highly concentrated in specific areas like anesthesiology, endocrinology and metabolism.
The findings are published in JAMA Network Open, as well as an Invited Commentary.
Identifying the superretractor concentration
To become a superretractor, first, a researcher must produce large volumes of unreliable, duplicate, or fabricated work, often fueled by the publish or perish system of academia that rewards output over rigor and lacks strong oversight. Second, that misconduct has to be uncovered through investigation and exposure.
Superretractors can also act as superspreaders of contaminated research. When flawed or fabricated trials enter systematic reviews and meta-analyses, they are amplified and woven into widely used evidence summaries. By the time a study is retracted, it has often already shaped these studies referenced for developing clinical guidelines that doctors rely on. The result is a cascade of distorted evidence that can translate into incorrect, even harmful, decisions in patient care.
A major concern is the rise of zombie studies—research that appears fake or lacks credible data yet remains in medical literature, often without being retracted by journals as it should be.
By pinpointing a small group of highly cited, influential authors behind many retractions, researchers can more quickly flag fraudulent and zombie literature at scale and trace related problematic studies through their co-author networks.
So, in this study, the researchers used a dataset called VITALITY, which includes 1,330 randomized clinical trials (RCTs) that have been retracted as of late 2024. They focused on three particular groups of scientists: superretractors on the Retraction Watch Leaderboard, scientists who are 2% of their subfield and have 10 or more retractions not due to editor or publisher errors, and top-cited scientists in 2024 who also have 10 or more such retractions.
They found that a very small group of people were responsible for a disproportionately large number of retracted medical trials. Of the 30 global superretractors, six individuals were involved with coauthoring 290 retracted trials and among the 163 highly influential scientists, just 18 were linked to 327 retracted trials.
Also, papers written by these high-profile authors remained in the scientific literature far longer before being retracted, taking an average of about 14 years, compared with just over a year for other researchers. As a result, these papers accumulated far more citations, allowing potentially flawed findings to spread more widely through the scientific community. Many of these authors also collaborated with other scientists whose papers were retracted, as co-authors.
These findings point to a clear need for systematic approaches to actively trace how untrustworthy data spreads and to prevent its continued contamination of the scientific record. The information highlighted in this study can guide journal editors, funders, and institutions in identifying high-risk authors and fields, directing attention where it is needed most.